Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
Completed
NCT02841774
High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
10
Enrollment(s)
1
Study location(s)
Interventional (Phase II)
HIV Infection
Coronary Heart Disease
Active, not recruiting
NCT02564900
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
292
Enrollment(s)
14
Study location(s)
Interventional (Phase I)
Advanced Solid Tumors
Recruiting
NCT03127631
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
6,000
Enrollment(s)
38
Study location(s)
Interventional (Not Applicable)
Prostate Cancer
Cardiovascular Disease
Completed
NCT02871687
Effect of Statin Use on Aldosterone Secretion
103
Enrollment(s)
1
Study location(s)
Interventional (Phase I)
Healthy Subjects
Terminated
NCT03989713
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
11
Enrollment(s)
1
Study location(s)
Interventional (Phase II)
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Recruiting
NCT05540587
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
240
Enrollment(s)
7
Study location(s)
Interventional (Phase II)
Mitral Valve Stenosis
Atrial Fibrillation
Stroke
Systemic Embolism
Recruiting
NCT04151680
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
100
Enrollment(s)
2
Study location(s)
Observational
Ischemic Heart Disease
Atrial Fibrillation
Recruiting
NCT04687761
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
84
Enrollment(s)
15
Study location(s)
Interventional (Phase I|Phase II)
Leukemia, Myeloid, Acute
De Novo
Age More 60yr
31
32
33
34
35